Identifying the Biggest Neuromuscular Advocacy Challenges for 2027: Paul Melmeyer, MPP

WATCH TIME: 3 minutes

For individuals living with neuromuscular diseases, access to specialized care, affordable treatments, and supportive services remains an important consideration alongside advances in therapeutic development. Although new treatments have expanded options for certain conditions, patients and families may continue to encounter barriers involving insurance coverage, medical equipment, clinical services, and disability accommodations. Addressing these challenges often requires coordination among patient advocacy organizations, health care professionals, researchers, and policymakers.

The Muscular Dystrophy Association (MDA) has supported these efforts through its Neuromuscular Advocacy Collaborative (NMAC), which brings together patient organizations representing a range of neuromuscular conditions. The collaborative provides a forum for identifying shared concerns, coordinating public policy initiatives, and strengthening advocacy around research funding, access to care, and disability rights. Its annual gathering at the MDA Clinical & Scientific Conference offers participating organizations an opportunity to reassess their priorities based on the experiences of the communities they represent.

“All of our organizations that are part of the Neuromuscular Advocacy Collaborative bring what we hear from our community to this meeting, so that we can focus in on those areas that are going to be most impactful.”

Ahead of the 2027 MDA Clinical & Scientific Conference, scheduled for March 21 to 24 in Orlando, Florida, NeurologyLive® spoke with Paul Melmeyer, MPP, executive vice president of public policy and advocacy at MDA. Melmeyer has played a central role in NMAC's continued development, including its expansion toward more frequent collaboration and coordinated advocacy activities throughout the year.

In the conversation, Melmeyer discussed how the collaborative intends to approach its 2027 meeting and determine which issues warrant the greatest attention. He outlined how feedback from patients and families could shape discussions around health insurance, access to treatments and medical devices, biomedical research funding, and opportunities for independent living, while emphasizing that the group's specific priorities will depend on the needs expressed by the community at the time of the meeting.